MSD Merck Sharp & Dohme Opens Global Innovation and Development Hub to ‘The Circle’ in Zurich
December 9, 2021 11:58 am ET
Zurich, December 9, 2021 – MSD Merck Sharp & Dohme AG known as Merck & Co, Inc, Kenilworth, N.J., USA in the United States and Canada (NYSE: MRK) – has opened the doors to its new Innovation and Development Hub in Zurich. The new MSD Zurich Hub at “The Circle” at Zurich Airport brings together more than 250 of MSD’s top R&D and marketing specialists from around the world.
MSD established a new globally-focused Innovation and Development Hub in Zurich, Switzerland, in line with its commitment to scientific excellence. The MSD Zurich Hub will further strengthen the company’s focus on innovative solutions for healthcare challenges using data processing, artificial intelligence and machine learning.
Dr Dean Li, president of MSD Research Laboratories, says: “Zurich provides an exceptional academic and life sciences ecosystem. The new MSD Hub will be a unique place where teams from all over the world collaborate and innovate in pursuit of MSD’s mission to save and improve lives.”
The global innovation hub at “The Circle” is a state-of-the-art activity-based working environment that fosters cross-functional collaboration. It co-locates some of MSD’s global and regional functions including Analytics, Biostatistics, Clinical Data Management, Data Science, Health Care Technology Assessment, Market Access, Marketing, Medical and Scientific Affairs, Real-World Evidence.
MSD has been operating in Switzerland for close to 60 years with four locations based in the Canton of Luzern. MSD has contributed to the development of the Swiss bio-pharmaceutical industry since 1963, when MSD first established its presence in Lucerne.
Today, MSD Switzerland employs around 1’000 people working in local, regional, and global functions in Human Health, Research and Development, Animal Health and Manufacturing.
“The Hub will be home to more than 250 people from a wide range of geographic backgrounds and functions, giving us the diversity of thought and experience required to continue to advance lifesaving solutions for patients,” said Frank Clyburn, executive vice president and president of Human Health for MSD.
The MSD Zurich Hub offices at The Circle have opened to employees at beginning of October 2021 in compliance with the applicable protective measures.
About MSD in Switzerland
MSD Switzerland employs over 1’000 people working in local, regional and global functions across four sites in the canton of Lucerne and one site in the canton of Zurich. Our business activities are subdivided in the two divisions, Human Health and Animal Health. MSD Human Health covers a broad range of biopharmaceuticals. Our areas of research and development are focusing on Oncology and Immuno-Oncology as well as Vaccines to prevent diseases for children, young people, and adults against Human Papilloma Virus (HPV), Ebola, Hepatitis, Pneumococcus, Meningococcus, Measles, Rubella, Chickenpox and Herpes Zoster. In addition, MSD is conducting research in the area of infectious diseases to find new therapeutic approaches for antibiotic resistance, HIV/Aids and Hepatitis C. Further research focuses include Immunology (auto-immune diseases) as well as Diabetes. MSD has a long-lasting legacy in contributing to major public health challenges, such as River Blindness, Ebola and SARS-CoV-2.
MSD Animal Health develops and markets products for the prevention, treatment and control of disease in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals’ well-being.
Our company has one of the largest clinical research programs worldwide. MSD Switzerland conducts 35 clinical trials per year for which the required medicines are manufactured at our research & development site in Schachen. The Schachen site operates since 2018 one of the three MSD forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products – an important contribution to patient safety.
At the newly opened Zurich site “The Circle”, our company sets the focus on research & development, data management and the commercialization of our medicines and vaccines. The Zurich hub offers a state-of-the-art work environment where our empowered, culturally diverse and inclusive workforce focuses on scientific excellence to improve people’s health.
MSD Switzerland plays an active role in its community and supports a range of local and regional initiatives as for example MSD for mothers, the health congress “Trendtage Gesundheit Luzern”, and the Swiss City Marathon Lucerne. Since 2013, MSD Switzerland has been continuously certified as a Top Employer and is pioneering a gender-neutral parental leave program for employees.
For more information www.msd.ch, www.de.msd-animal-health.chFollow-us on Twitter, LinkedIn, Facebook and YouTube.
About MSD
For more than 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.
For more information, visit http://www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
MSD Switzerland
media.switzerland@msd.com | Tel. 058 618 30 30
Jean-Blaise Defago (Policy & Communications Director)
© 2021 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Luzern. Alle Rechte vorbehalten.
CH-NON-01456, 12/21
